Sartorius Stedim Biotech appointed Dr Lothar Kappich to its Board of Directors

– FRANCE, Aubagne – Sartorius Stedim Biotech S.A. (Paris:DIM) announced that the Board of Directors resolved to appoint Dr. Lothar Kappich as a member of the Board. This election was required after former member Professor Arnold Picot, Ph.D., had unexpectedly passed away in July 2017.

Lothar Kappich, age 60, holds a university degree in economics and was the Managing Director of the real estate development company ECE Projektmanagement GmbH & Co. KG until he reached this company’s age limit for management board executives. Kappich is also Chairman of the Supervisory Board of SSB’s major shareholder Sartorius AG.

The SSB Board now consists of four men and three women: Joachim Kreuzburg (Chairman), Susan Dexter, Anne-Marie Graffin, Lothar Kappich, Liliane de Lassus, Bernard Lemaître and Henri Riey.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2016, the company employed approx. 4,700 people, and earned sales revenue of 1,051.6 million euros.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>